Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,297 papers from all fields of science
Search
Sign In
Create Free Account
L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein
Known as:
L19-IL2
An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PO-428 Radiotherapy, immunocytokines and immune checkpoint inhibitors: finding the optimal combination
V. O. Pimentel
,
D. Marcus
,
+7 authors
P. Lambin
ESMO Open
2018
Corpus ID: 81899395
Introduction Although immunotherapy is currently changing cancer treatment practice, primary resistance is still seen partly due…
Expand
2016
2016
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patients.
C. Garbe
,
A. Romanini
,
+7 authors
T. Eigentler
Journal of Clinical Oncology
2016
Corpus ID: 21987634
9064 Background:L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format directed…
Expand
2016
2016
Radiotherapy and the immunocytokine L19-IL2: a perfect match for an abscopal effect with long-lasting memory
L. Dubois
,
N. Rekers
,
+6 authors
P. Lambin
2016
Corpus ID: 73806415
2015
2015
Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Niklas Börschel
,
C. Schwöppe
,
+9 authors
C. Schliemann
Leukemia research : a Forum for Studies on…
2015
Corpus ID: 23846879
2014
2014
Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.
D. Neri
,
B. Weide
,
+9 authors
C. Garbe
2014
Corpus ID: 78862262
9041^ Background: In previous studies, intralesional injection with interleukin-2 (IL2) showed efficacy for the intratumoral…
Expand
2014
2014
A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions.
R. Danielli
,
R. Patuzzo
,
+11 authors
M. Maio
2014
Corpus ID: 78743928
TPS9103^ Background: Preclinical studies in three different murine models of subcutaneous tumors have shown that a single…
Expand
2014
2014
OC-0249: Radiotherapy and L19-IL2 are able to synergize: long-lasting antitumor effects
N. Rekers
,
C. Zegers
,
+7 authors
P. Lambin
2014
Corpus ID: 76179100
2011
2011
A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma.
T. Eigentler
,
B. Weide
,
+12 authors
C. Garbe
Journal of Clinical Oncology
2011
Corpus ID: 9553890
2531 Background: L19-IL2 is a tumor-targeting immunocytokine composed of an antibody fragment specific to the EDB domain of…
Expand
2010
2010
Entwicklung und funktionelle Analyse eines zellbasierten Bioaktivitätstests für das Immunzytokin L19-IL2
Jonas P. Winter
2010
Corpus ID: 83694840
2008
2008
Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma
M. Johannsen
,
A. Roemer
,
+7 authors
F. Braud
2008
Corpus ID: 57408999
16032 Background: L19-IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE